Investigating a new cancer therapy using translation initiation inhibitors
Official title: Translation Initiation Inhibitor for Cancer Therapy
Funded at Herbert H. Lehman College · NIH-11080969 · Data updated 2026-11-12
This study is looking at how a substance called Interleukin-24 (IL-24) can help kill cancer cells and shrink tumors while being gentle on healthy cells, with the goal of creating a new treatment for solid tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Herbert H. Lehman College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $143,196 |
| NIH project number | 5R16GM145561-04 |
| Project ID | NIH-11080969 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who are seeking new treatment options.
✕Less likely to help
Patients with non-solid tumors or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on understanding how inhibiting translation initiation can lead to cancer cell death and tumor suppression through the action of Interleukin-24 (IL-24). By exploring the cellular mechanisms involved, the study aims to develop a targeted cancer therapy that minimizes harm to normal cells while effectively combating tumors. The approach includes both laboratory studies and in vivo testing to assess the safety and efficacy of IL-24 as a potential treatment for solid tumors.
Why it matters
Potential benefit: If successful, this research could lead to a novel cancer therapy that is more effective and has fewer side effects than current treatments.
How similar studies have gone: Previous clinical testing of IL-24 has shown promising results, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
Herbert H. Lehman College
New York, United States Active
Researchers
- Principal investigator: Sauane, Moira — Herbert H. Lehman College
- Study coordinator: Sauane, Moira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.